BRPI0813450A2 - Composto, composição, combinação, formulação farmacêutica, e, métodos para inibir uma enzima, para exterminar ou prevenir o crescimento de um microorganismo e para tratar e/ou prevenir uma doença em um animal - Google Patents

Composto, composição, combinação, formulação farmacêutica, e, métodos para inibir uma enzima, para exterminar ou prevenir o crescimento de um microorganismo e para tratar e/ou prevenir uma doença em um animal

Info

Publication number
BRPI0813450A2
BRPI0813450A2 BRPI0813450-2A2A BRPI0813450A BRPI0813450A2 BR PI0813450 A2 BRPI0813450 A2 BR PI0813450A2 BR PI0813450 A BRPI0813450 A BR PI0813450A BR PI0813450 A2 BRPI0813450 A2 BR PI0813450A2
Authority
BR
Brazil
Prior art keywords
prevent
extermine
microorganism
inhibit
enzyme
Prior art date
Application number
BRPI0813450-2A2A
Other languages
English (en)
Inventor
Stephen J Baker
Vincent S Hernandez
Rashmi Sharma
James A Nieman
Tsutoma Akama
Yong-Kang Zhang
Jacob J Plattner
Michael Richard Kevin Alley
Rajeshwar Singh
Minh Ha
Xiaosong Lu
El Mehdi Keramane
Huchen Zhou
Yi Xia
James G Philips
Rahim Mohammad
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40156702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813450(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of BRPI0813450A2 publication Critical patent/BRPI0813450A2/pt
Publication of BRPI0813450B1 publication Critical patent/BRPI0813450B1/pt
Publication of BRPI0813450B8 publication Critical patent/BRPI0813450B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0813450A 2007-06-20 2008-06-19 composto, formulação farmacêutica, e, usos do composto BRPI0813450B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94529407P 2007-06-20 2007-06-20
US60/945,294 2007-06-20
US4117808P 2008-03-31 2008-03-31
US61/041,178 2008-03-31
PCT/US2008/067550 WO2008157726A1 (en) 2007-06-20 2008-06-19 Boron-containing small molecules

Publications (3)

Publication Number Publication Date
BRPI0813450A2 true BRPI0813450A2 (pt) 2014-12-30
BRPI0813450B1 BRPI0813450B1 (pt) 2019-05-07
BRPI0813450B8 BRPI0813450B8 (pt) 2021-05-25

Family

ID=40156702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813450A BRPI0813450B8 (pt) 2007-06-20 2008-06-19 composto, formulação farmacêutica, e, usos do composto

Country Status (29)

Country Link
US (4) US7816344B2 (pt)
EP (1) EP2164331B1 (pt)
JP (3) JP5530923B2 (pt)
KR (3) KR20150100945A (pt)
CN (2) CN104017008A (pt)
AR (1) AR067105A1 (pt)
AU (1) AU2008265630B2 (pt)
BR (1) BRPI0813450B8 (pt)
CA (1) CA2692135C (pt)
CL (1) CL2008001855A1 (pt)
CO (1) CO6251209A2 (pt)
CR (1) CR11224A (pt)
DK (1) DK2164331T3 (pt)
DO (1) DOP2009000281A (pt)
EA (1) EA020530B1 (pt)
ES (1) ES2655299T3 (pt)
IL (1) IL202379A (pt)
JO (1) JO3396B1 (pt)
MA (1) MA31675B1 (pt)
MX (1) MX347688B (pt)
MY (1) MY162692A (pt)
NO (1) NO2164331T3 (pt)
NZ (1) NZ582706A (pt)
PE (1) PE20090840A1 (pt)
SG (1) SG182219A1 (pt)
TW (1) TW200911822A (pt)
UY (1) UY31171A1 (pt)
WO (1) WO2008157726A1 (pt)
ZA (2) ZA200909003B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
NZ570257A (en) 2006-02-16 2011-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
CA2651212A1 (en) 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
BRPI0908565A2 (pt) * 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
MX2011006334A (es) * 2008-12-17 2011-09-22 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
KR20130031233A (ko) 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110212918A1 (en) * 2009-11-11 2011-09-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
JP5603998B2 (ja) * 2010-04-07 2014-10-08 グラクソスミスクライン エルエルシー ベンゾオキサボロールの調製方法
SG10201507032YA (en) * 2010-09-07 2015-10-29 Anacor Pharmaceuticals Inc Benzoxaborole derivatives for treating bacterial infections
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
US9162999B2 (en) 2011-09-28 2015-10-20 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
US8530452B2 (en) 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
US20150080342A1 (en) 2012-04-14 2015-03-19 Anacor Pharmaceuticals, Inc. Benzoxaborole compounds and uses thereof
DK2950644T3 (en) 2013-01-30 2017-09-04 Agrofresh Inc USE OF BENZOXABOROLS AS VOLATIVE ANTIMICROBIAL AGENTS IN MEAT, PLANTS OR PARTS
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
AP2015008638A0 (en) 2013-02-01 2015-08-31 Anacor Pharmaceuticals Inc Boron-containing small molecules as antiprotozoal agents
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
KR101636431B1 (ko) * 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
CN105492388B (zh) 2013-08-09 2018-12-21 葛兰素史克知识产权第二有限公司 三环苯并氧杂硼杂环戊烯化合物及其用途
EA038093B1 (ru) * 2013-12-20 2021-07-05 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Способ лечения заболевания, вызванного инфекцией комплекса mycobacterium tuberculosis, с использованием (s)-(3-хлор-7,8-дигидро-2h-1,6,9-триокса-9a-борабензо[cd]азулен-2-ил)метанамина или его фармацевтически приемлемой соли
MX2016010451A (es) * 2014-02-17 2016-09-22 Syngenta Participations Ag Benzoxaboroles microbicidamente activos.
JP6605513B2 (ja) 2014-07-01 2019-11-13 第一三共株式会社 抗菌剤としての三環式ベンゾオキサボロール
US9738664B2 (en) * 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
BR112017021478B1 (pt) 2015-04-09 2022-04-19 The Penn State Research Foundation Composição antifúngica sinérgica que contém benzoxaborol
CA3014757C (en) * 2015-08-06 2020-01-14 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
US10611781B2 (en) 2016-03-02 2020-04-07 Bill And Melinda Gates Foundation Boron-containing small molecules
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
CN113321672A (zh) 2016-03-02 2021-08-31 比尔及梅琳达盖茨基金会 含硼小分子
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
HK1258717A1 (zh) 2016-05-12 2019-11-15 安纳考尔医药公司 氧杂硼杂环戊烷酯类及其用途
EP3609504A4 (en) 2017-03-01 2021-03-03 Anacor Pharmaceuticals, Inc. NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
CN107090000B (zh) * 2017-04-27 2019-07-12 上海交通大学 一种苯并硼唑7位脂肪酸的衍生物及其制备与用途
FI3639005T3 (fi) 2017-06-13 2024-07-25 Veterinary Diagnostics Inst Inc Menetelmä verinäytteiden uuttamiseksi kuivatuista veripisaroista
BR112020010927A2 (pt) * 2017-11-30 2020-12-01 Boragen, Inc. compostos de benzoxaborol e formulações dos mesmos
CA3120974A1 (en) * 2017-11-30 2019-06-06 Boragen, Inc. Combinatorial compositions of benzoxaboroles and biologic agents
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
AR116305A1 (es) * 2018-09-07 2021-04-21 Boragen Inc Compuestos que contienen boro y sus usos
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
EP4204012A1 (en) 2020-08-31 2023-07-05 Pfizer Inc. Methods of protecting rna
US20250000883A1 (en) * 2021-10-29 2025-01-02 An2 Therapeutics, Inc. Treating neuroinflammatory conditions
CN119233823A (zh) * 2022-06-23 2024-12-31 上海盟科药业股份有限公司 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
CN119233977B (zh) * 2022-06-23 2026-03-17 上海盟科药业股份有限公司 硼化合物的前药及其在治疗细菌感染中的用途
US12482208B2 (en) 2023-05-30 2025-11-25 Snap Inc. Mirroring 3D assets for virtual experiences

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2002006316A2 (en) 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
US6537733B2 (en) * 2001-02-23 2003-03-25 Applied Materials, Inc. Method of depositing low dielectric constant silicon carbide layers
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
JPWO2003033002A1 (ja) 2001-10-11 2005-02-03 御子柴　克彦 細胞内カルシウム濃度上昇抑制剤
AU2003205089B2 (en) 2002-01-10 2007-01-25 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
RU2359967C2 (ru) * 2002-05-28 2009-06-27 Джонсон энд Джонсон Фамэсьютикэл Рисеч энд Дивелопмент, эЛ.эЛ.Си Производные тиофена и фармацевтическая композиция (варианты)
BRPI0411582A (pt) * 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
US7767657B2 (en) * 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5038912B2 (ja) * 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
NZ570257A (en) 2006-02-16 2011-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
RU2008152367A (ru) 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
DE102006038471A1 (de) 2006-08-17 2008-04-10 Wala-Heilmittel Gmbh Platanencreme, Verfahren zu ihrer Herstellung und Verwendung
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Also Published As

Publication number Publication date
JP6570391B2 (ja) 2019-09-04
CN101772302B (zh) 2014-05-07
PE20090840A1 (es) 2009-07-08
CO6251209A2 (es) 2011-02-21
US20180016285A1 (en) 2018-01-18
JP2014148531A (ja) 2014-08-21
KR20100051615A (ko) 2010-05-17
AR067105A1 (es) 2009-09-30
JO3396B1 (ar) 2019-10-20
IL202379A0 (en) 2010-06-30
SG182219A1 (en) 2012-07-30
BRPI0813450B8 (pt) 2021-05-25
JP2010530881A (ja) 2010-09-16
EP2164331A1 (en) 2010-03-24
ZA200909003B (en) 2022-03-30
ES2655299T3 (es) 2018-02-19
CA2692135C (en) 2017-01-24
CL2008001855A1 (es) 2009-05-29
CR11224A (es) 2010-06-28
TW200911822A (en) 2009-03-16
AU2008265630B2 (en) 2013-06-20
JP5530923B2 (ja) 2014-06-25
EA020530B1 (ru) 2014-11-28
KR20160049025A (ko) 2016-05-04
NZ582706A (en) 2012-07-27
BRPI0813450B1 (pt) 2019-05-07
US20150133402A1 (en) 2015-05-14
CA2692135A1 (en) 2008-12-24
UY31171A1 (es) 2009-04-30
JP2016040275A (ja) 2016-03-24
US8895534B2 (en) 2014-11-25
EP2164331B1 (en) 2017-11-29
US9796735B2 (en) 2017-10-24
IL202379A (en) 2016-02-29
CN104017008A (zh) 2014-09-03
AU2008265630A1 (en) 2008-12-24
MY162692A (en) 2017-07-14
KR101685656B1 (ko) 2016-12-12
KR101578351B1 (ko) 2015-12-17
CN101772302A (zh) 2010-07-07
NO2164331T3 (pt) 2018-04-28
US20100292504A1 (en) 2010-11-18
US10533021B2 (en) 2020-01-14
DK2164331T3 (da) 2018-01-29
WO2008157726A1 (en) 2008-12-24
ZA201104573B (en) 2014-03-26
KR20150100945A (ko) 2015-09-02
DOP2009000281A (es) 2010-07-31
US7816344B2 (en) 2010-10-19
MA31675B1 (fr) 2010-09-01
MX347688B (es) 2017-05-09
EA200901617A1 (ru) 2010-06-30
EP2164331A4 (en) 2011-09-07
US20090227541A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
BRPI1012219A2 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BRPI0811542A2 (pt) Composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e para tratar ou prevenir uma patologia relacionada com abeta em um mamífero composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e, para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0822162A8 (pt) método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BRPI0923758A2 (pt) "derivados de pirimidina e seu emprego para o combate ao crescimento indesejado de plantas".
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
WO2010001169A3 (en) Chemical compounds 251
BRPI0920261A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0820068A2 (pt) Composição para nutrição humana e/ou animal, usos derivados e leveduras
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BRPI0910359A2 (pt) método para inibir o crescimento de microorganismos e composição biocida
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
BRPI0916043A2 (pt) composição farmacêutica e alimento funcional para prevenir ou tratar câncer
BRPI0915471A2 (pt) composto, composição farmacêutica, métodos de inibir dna girase bacteriana e/ou topoisomerase bacteriana iv, para produzir um efeito antibacteriano em um animal de sangue quente e para tratar uma infecção bacteriana em um animal de sangue quente, e, uso de um composto
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0813159A2 (pt) Composição parasiticida veterinária, método para o tratamento ou controle de uma infecção ou infestação parasiticidas em um animal homeotérico, e, uso de uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B25D Requested change of name of applicant approved

Owner name: ANACOR PHARMACEUTICALS, LLC (US)

B25G Requested change of headquarter approved

Owner name: ANACOR PHARMACEUTICALS, LLC (US)

B25G Requested change of headquarter approved

Owner name: ANACOR PHARMACEUTICALS, LLC (US)